The trophoblastic disease includes different types of pathologic events classified and divided by the WHO in 2003. It includes hydatidiform mole, invasive mole, choriocarcinoma and placental site trophoblastic tumor. Most of those pathologies are chemosensitive and have excellent prognosis, allowing preserving women’s fertility because of the low relapse rate during further pregnancies. Physiopathological mechanisms and risk factors are now better understood. Hydatidiform moles have to be treated by suction rather than curettage. Placental site trophoblastic tumors are particularly chemoresistant, not secreting hCG which needs specific management. Trophoblastic tumors can be divided into two groups: a low risk group treated by monotherapy, most often by Methotrexate1 or Actinomycine D, with survey about 100%, and a high risk group treated by polychemotherapy (Etoposide1, Methotrexate1, actinomycine D, cyclophosphamide, Vincristine1) with survey rate of 86%. This study highlights the importance of early diagnosis for performing a rapid and targeted treatment, to preserve the procreative ability of the woman who most of the times is young and desirous of maternity.
Gestational trophoblastic disease
Vitale, S. G.;
2013-01-01
Abstract
The trophoblastic disease includes different types of pathologic events classified and divided by the WHO in 2003. It includes hydatidiform mole, invasive mole, choriocarcinoma and placental site trophoblastic tumor. Most of those pathologies are chemosensitive and have excellent prognosis, allowing preserving women’s fertility because of the low relapse rate during further pregnancies. Physiopathological mechanisms and risk factors are now better understood. Hydatidiform moles have to be treated by suction rather than curettage. Placental site trophoblastic tumors are particularly chemoresistant, not secreting hCG which needs specific management. Trophoblastic tumors can be divided into two groups: a low risk group treated by monotherapy, most often by Methotrexate1 or Actinomycine D, with survey about 100%, and a high risk group treated by polychemotherapy (Etoposide1, Methotrexate1, actinomycine D, cyclophosphamide, Vincristine1) with survey rate of 86%. This study highlights the importance of early diagnosis for performing a rapid and targeted treatment, to preserve the procreative ability of the woman who most of the times is young and desirous of maternity.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.